CEACAM5 and pancreatic intraductal papillary-mucinous neoplasm: The malignant and benign IPMN subgroups differed in terms of their serum biomarker levels, with the invasive IPMN subgroup having higher CA19-9 levels (149.4 vs. 20.4 U/ml, p < 0.0001), higher CA125 levels (17.6 vs. 11.8 U/ml, p = 0.0056) and higher CEA levels (5.27 vs. 2.71 μg/L, p = 0.0026) (Fig. 1).